XPro1595 for Alzheimer's Disease

Recruiting at 5 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Inmune Bio, Inc.

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial tests XPro1595, a drug for Alzheimer's Disease, on people who were in previous studies. It aims to see if regular injections can reduce brain inflammation and improve memory and daily activities.

Research Team

Tara Lehner

Principal Investigator

INmune Bio

Eligibility Criteria

This trial is for individuals who completed a previous XPro1595 study for Alzheimer's, can consent (or have a representative do so), and have a partner to assist them. They must maintain stable doses of current Alzheimer's medications and agree to contraception if applicable. Those with unstable medical conditions or unable to follow the study plan are excluded.

Inclusion Criteria

My medications for mild cognitive impairment or Alzheimer's disease will stay the same during this study.

All females of childbearing potential (FCBP) must have a negative urine pregnancy test and agree to use a highly effective method of contraception during the treatment period and 30 days after the last dose of treatment

Participated and completed the full duration of the study intervention and all procedures at the End of Study (EOS) visit in a previous XPro1595 study

Exclusion Criteria

I can follow the study's procedures and assessments.

I don't have any health issues that could affect my safety in the study.

Treatment Details

Interventions

• XPro1595 (Cytokine Inhibitor)

Trial Overview The Phase 2 trial tests the long-term safety and effectiveness of XPro1595 on cognitive function, daily activities, and brain health in people with Alzheimer's Disease. It’s an open-label extension meaning everyone gets the drug and there’s no placebo comparison.

Participant Groups

Group I: Experimental: 1.0 mg/kg XPro1595 Experimental Treatment 1 Intervention

Patients will receive XPro1595.

Who Is Running the Clinical Trial?

Inmune Bio, Inc.

Lead Sponsor

Trials

7

Recruited

340+